
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings Inc. has demonstrated robust growth with DEFINITY achieving a low-to-mid-teens increase in the second half of 2024, bolstered by a competitor's absence in the market. The company is projected to see free cash flow expansion to an estimated $550M-$600M by 2025, up from $493M in 2024, indicating strong financial health and operational efficiency. Additionally, anticipated market expansion in the diagnostic imaging sector, driven by evolving guidelines and positive clinical data, positions Lantheus for significant growth over the coming years.
Bears say
Lantheus Holdings Inc. faces a negative outlook due to decelerating growth trends, notably stemming from the expiration of Pylarify's intellectual property, which is expected to result in low-single-digit (LSD) year-over-year earnings per share (EPS) dilution in the near term. Additionally, the forecasted growth for DEFINITY is projected at low-single-digit to mid-single-digit (LSD-MSD), significantly underperforming against long-term expectations, alongside anticipated quarterly fluctuations indicating stagnation or negative growth. Moreover, the company is confronted by various risks, including increased competition in the prostate-specific membrane antigen (PSMA) PET segment, uncertainties surrounding new indications, and potential headwinds from Medicare reimbursement policies that could exacerbate pricing pressures.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares